Marisol
Aymerich Soler
Catedrática de Universidad
Publications (61) Marisol Aymerich Soler publications
2024
-
Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity
Journal of Neuroinflammation, Vol. 21, Núm. 1
2023
-
El núcleo: parte II, transcripción y maduración del ARN, y estructura del nucléolo
Biología celular biomédica (Elsevier), pp. 175-197
-
Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease
GLIA, Vol. 71, Núm. 3, pp. 571-587
-
Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models
Neurobiology of Disease, Vol. 183
2021
-
Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice
Antioxidants, Vol. 10, Núm. 8
-
Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Understanding the potential role of sirtuin 2 on aging: Consequences of sirt2.3 overexpression in senescence
International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-23
2020
-
Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease
Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1 (Elsevier), pp. 557-573
-
Cb2 receptors and neuron–glia interactions modulate neurotoxicity generated by magl inhibition
Biomolecules, Vol. 10, Núm. 8, pp. 1-15
2019
-
Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model
Frontiers in Immunology, Vol. 10, Núm. MAY
-
Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions
Journal of Neuroinflammation, Vol. 16, Núm. 1
2018
-
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Biochemical Pharmacology, Vol. 157, pp. 67-84
-
Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples
Neurotherapeutics, Vol. 15, Núm. 3, pp. 742-750
-
Stereological estimates of glutamatergic, GABAergic, and cholinergic neurons in the pedunculopontine and laterodorsal tegmental nuclei in the rat
Frontiers in Neuroanatomy, Vol. 12
-
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia
Neurobiology of Disease, Vol. 118, pp. 64-75
2017
-
GPR55: A therapeutic target for Parkinson's disease?
Neuropharmacology, Vol. 125, pp. 319-332
-
Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease
Neuropharmacology, Vol. 113, pp. 110-123
-
Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks
Neuroscience and Biobehavioral Reviews, Vol. 76, pp. 380-395
2016
-
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease
Brain, Behavior, and Immunity, Vol. 57, pp. 94-105
-
Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors
Molecular Neurobiology, Vol. 53, Núm. 4, pp. 2312-2319